Zhengye Biotechnology Holding Limited(ZYBT)Earnings, Financials & Key Ratios
ZYBT•NASDAQ
$0.68
Price updated Jul 2, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryAnimal health pharmaceuticals and vaccines
AboutZhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.Show more
- Revenue$186M-12.0%
- EBITDA$41M-41.1%
- Net Income$11M-64.0%
- EPS (Diluted)0.00
- Gross Margin48.99%-20.2%
- EBITDA Margin21.79%-33.1%
- Operating Margin8.82%-58.5%
- Net Margin6.07%-59.2%
- ROE3.27%-63.8%
ZYBT Price & Volume
Zhengye Biotechnology Holding Limited (ZYBT) stock price & volume — 10-year historical chart
Loading chart...
Revenue Contraction Challenges Specialized Biological Manufacturing Model
Investment Thesis • Updated N/A
VerdictNegative
Growth:Contracting
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Swine cycle demand volatility
Key Thesis Takeaways
- Zhengye Biotechnology faces significant headwinds as its 11.95% year-over-year revenue decline highlights the vulnerability of its government-tender business model to regional swine cycle volatility.
- While the firm maintains a defensive posture with a 0.25 debt-to-equity ratio, the compression of operating margins to 6.07% suggests that high fixed costs for P3 laboratory maintenance may continue to limit profitability.
- Investors should monitor whether the company can leverage its $18.6 million cash reserve to pivot toward more sustainable commercial markets or if structural margin pressures will persist.
Verdict Logic
the combination of an 11.95% revenue decline and a compressed 6.07% operating margin suggests that the firm's specialized manufacturing model currently lacks the scale to overcome sector-specific demand downturns.
ZYBT Growth Metrics
Zhengye Biotechnology Holding Limited (ZYBT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-4.52%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-33.78%
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years13.19%
5 Years13.19%
3 Years12.12%
Last Year4.65%
Peers Comparison
Key metrics vs top competitors for Zhengye Biotechnology Holding Limited (ZYBT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.68 | $30.92M | — | -11.95% | 6.07% | 3.27% | 7.63% | |
| $3.42 | $1.97M | -0.55 | 28.47% | -201.97% | -31.72% | — | |
| $0.85 | $25.28M | -3.27 | 15.17% | -3.05% | -15.02% | — | |
| $1.44 | $1.44M | -0.18 | -15.97% | -19.58% | -46.71% | — | |
| $1.07 | $3.5M | -1.60 | -70.11% | -33.27% | -28.25% | — | |
| $0.77 | $311.84K | -0.02 | -100% | -3666.64% | -91.85% | — |
Compare ZYBT vs Peers
Zhengye Biotechnology Holding Limited (ZYBT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ZYBT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZYBT Frequently Asked Questions
Zhengye Biotechnology Holding Limited (ZYBT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Zhengye Biotechnology Holding Limited's revenue?
Zhengye Biotechnology Holding Limited (ZYBT) reported $186.4M in revenue for fiscal year 2024. This represents a 13% decrease from $214.1M in 2021.
How fast is Zhengye Biotechnology Holding Limited growing?
Zhengye Biotechnology Holding Limited (ZYBT) saw revenue decline by 12.0% over the past year.
Is ZYBT profitable?
Yes, Zhengye Biotechnology Holding Limited (ZYBT) is profitable, generating $11.3M in net income for fiscal year 2024 (6.1% net margin).
Dividend & Returns
Does ZYBT pay dividends?
Yes, Zhengye Biotechnology Holding Limited (ZYBT) pays a dividend with a yield of 7.63%. This makes it attractive for income-focused investors.
What is ZYBT's return on equity?
Zhengye Biotechnology Holding Limited (ZYBT) has a return on equity (ROE) of 3.3%. This is below average, suggesting room for improvement.
What is Zhengye Biotechnology Holding Limited's free cash flow?
Zhengye Biotechnology Holding Limited (ZYBT) generated $13.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.